fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Chevron To Exit Operations In Myanmar – $CVX $DIA $ATOS

By John F. Heerdink, Jr.

Reportedly, Chevron Corporation (CVX) is to sell its assets in Myanmar to Canadian company MTI, in a deal that allows the oil major to leave the Asian country. The deal comes one year after Chevron and other major oil companies announced leaving Myanmar following a military coup in 2021. Chevron and other oil majors have condemned human rights abuses in the Asian country.

The company has agreed to sell for an undisclosed amount of its 41.1% interest in the Yadana Project to a subsidiary of MTI. Yadana deals with the production of natural gas for domestic use and export to Thailand.

Dow 30 component Chevron Corporation (CVX), through its subsidiaries, engages in integrated energy, chemicals, and petroleum operations worldwide.  To learn more about Chevron (CVX) and to track their progress please visit the Vista Partners Chevron Page.


Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


DID YOU KNOW?…

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today (Feb. 13, 2023) announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,572,334) directed to (Z)-endoxifen encapsulated in an enteric capsule. Enteric capsules have an acid resistant coating to prevent them from dissolving when they pass through the stomach. Enteric capsules are dissolved when they pass through an alkaline environment, which is usually when they reach the small intestine. Delivering oral (Z)-endoxifen via an enteric capsule prevents breakdown of the endoxifen in the stomach.

This patent further reinforces Atossa’s broad Intellectual Property portfolio related to (Z)-endoxifen. Atossa is developing its proprietary (Z)-endoxifen in both the breast cancer treatment and prevention settings. Phase 2 trials are ongoing with the goal of changing the treatment paradigm for patients who are not benefiting from currently approved drugs and helping reduce the incidence of breast cancer.

A short ‘explainer’ video about the new patent can be found here: Patent Update – Video Explainer. 

Atossa Therapeutics

Learn more by clicking here. 

(Read Original Story: Chevron agrees to sell Myanmar assets and will exit country in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us